Sodium-Glucose Transporter 2 Inhibitors: all 1,276 studies that test it
Page 11 of 13. Open to participants first (266), then studies with results posted, then the rest; newest registration first within each.
- Dapagliflozin During Exercise for the PrevenTion of HypoglycaemiaTerminatedNCT03537131Phase 2
- Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and EmpagliflozinCompletedNCT03510000Not applicable
- Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2)WithdrawnNCT03504566Phase 4
- Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic EffectsCompletedNCT03485092Phase 4
- Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate HypertensionCompletedNCT03462069Phase 2
- The Efficacy of Sodium-glucose Co-transporter 2 Inhibitor or Dipeptidyl Peptidase-4 Inhibitor in Type 2 Diabetes Patients With Premix InsulinStatus unknownNCT03458715Phase 4
- Empagliflozin Effect on Glucose ToxicityWithdrawnNCT03437330Phase 4
- Renal Actions of Combined Empagliflozin and LINagliptin in Type 2 diabetESStatus unknownNCT03433248Phase 4
- Glucose Absorption and Gut Hormone Secretion After Gastric BypassStatus unknownNCT03426956Not applicable
- Dapagliflozin Effect on Erythropoiesis and Physical FitnessWithdrawnNCT03423355Phase 4
- The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant PatientsTerminatedNCT03419624Phase 3
- Absolute Bioavailability Study With BexagliflozinWithdrawnNCT03417076Phase 1
- A Drug-Drug Interaction Study Between Sotagliflozin and RamiprilCompletedNCT03414723Phase 1
- Effects of SGLT2 Inhibitor in Diabetic Patients With Coronary Artery DiseaseStatus unknownNCT03398577Phase 4
- A Drug to Drug Interaction Study of Sotagliflozin With HydrochlorothiazideCompletedNCT03387657Phase 1
- Dapagliflozin, Cardio-Metabolic Risk Factors and Type-2 DiabetesStatus unknownNCT03377335Phase 4
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP16001 After Oral Administration in Healthy Male VolunteersCompletedNCT03364985Phase 1
- DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2CompletedNCT03361098Phase 4
- A Phase IV Study in Drug-Naive Patients With T2DM in ChinaTerminatedNCT03344341Phase 4
- Effects of SGLT2 Inhibition on Myocardial Insulin SensitivityCompletedNCT03313752Phase 3
- Comparison of Sotagliflozin Prototype Tablets With Reference Tablet in Healthy SubjectsCompletedNCT03310944Phase 1
- Impact of a Short-term Treatment With Canagliflozin (Canacardia-HF)WithdrawnNCT03298009Not applicable
- SGLT2i and Incretin and CRTd.CompletedNCT03282136Phase 4
- Evaluate the Effects of Dapagliflozin in Patients With Type 2 DiabetesCompletedNCT03269058Phase 4
- Empagliflozin and Sympathetic Nerve TrafficCompletedNCT03254849Phase 4
- Effect of Empagliflozin Versus Placebo on Brain Insulin Sensitivity in Patients With PrediabetesCompletedNCT03227484Phase 2
- Empagliflozin and the Preservation of Beta-cell Function in Women with Recent Gestational DiabetesCompletedNCT03215069Phase 3
- Sotagliflozin Bioequivalence StudyCompletedNCT03211195Phase 1
- Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery DiseaseCompletedNCT03208465Phase 4
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx StudyCompletedNCT03202667Phase 2/3
- Postprandial Hypoglycemia in Patients After Bariatric Surgery With Empagliflozin and Anakinra - The Hypo-BEAR-StudyCompletedNCT03200782Not applicable
- Empagliflozin in Heart Failure Patients With Reduced Ejection FractionCompletedNCT03198585Phase 2
- Effects of Canagliflozin on Intravascular Volume and HemodynamicsWithdrawnNCT03190798Phase 4
- Effects of DPP4 Inhibitor Versus SGLT2 InhibitorCompletedNCT03178591Phase 4
- A Study to Evaluate the Effect of Food on the Pharmacokinetics of Sotagliflozin and to Explore the Relative Bioavailability in Healthy SubjectsCompletedNCT03174548Phase 1
- Empaglifozin in Early Diabetic Kidney DiseaseWithdrawnNCT03173963Phase 3
- A Study to Evaluate the Food Effect on Drug Availability, Pharmacokinetic (PK) Properties, Safety and Tolerability of Two Different Dose Combination Therapy of Saxagliptin/Dapagliflozin/Metformin Extended-release (XR) Against Individual Component Co-administration.CompletedNCT03169959Phase 1
- Empagliflozin in Renal Transplant RecipientsCompletedNCT03157414Phase 4
- SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular RiskCompletedNCT03151343Phase 3
- Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy SubjectsCompletedNCT03138356Phase 1
- Empagliflozin as a Modulator of Systemic Vascular Resistance and Cardiac Output in Patients With Type 2 DiabetesCompletedNCT03132181Phase 2
- Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart FailureCompletedNCT03128528Phase 2
- A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With AlbuminuriaTerminatedNCT03118713Phase 4
- Impact of Empaglifozine on Cardiac Ectopic FatCompletedNCT03118336Phase 3
- Empagliflozin in Post-Transplantation Diabetes MellitusCompletedNCT03113110Phase 2
- Empagliflozin and Renal Oxygenation in Healthy VolunteersCompletedNCT03093103Phase 2
- Effects of SGLT2 Inhibitor on Hemodynamic Parameters in Resistant Hypertensive SubjectsCompletedNCT03089333Phase 4
- EMPRA (EMPagliflozin and RAs in Kidney Disease)CompletedNCT03078101Phase 2
- Efficacy of Ipragliflozin Compared With Sitagliptin in Uncontrolled Type 2 Diabetes With Sulfonylurea and MetforminCompletedNCT03076112Phase 3
- Interaction Study to Evaluate the Effects of Mefenamic Acid on the Pharmacokinetics and Pharmacodynamics of Sotagliflozin in Healthy Male and Female SubjectsCompletedNCT03070678Phase 1
- Effect of Rifampicin on the Pharmacokinetics and Pharmacodynamics of SotagliflozinCompletedNCT03063580Phase 1
- Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on MetforminTerminatedNCT03060980Phase 3
- Pharmacokinetic Evaluation of EmpagliflozinCompletedNCT03059056Phase 1
- SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)CompletedNCT03050229Phase 4
- Empagliflozin in Heart Failure: Diuretic and Cardio-Renal EffectsCompletedNCT03027960Phase 1
- Empagliflozin vs Metformin in PCOSCompletedNCT03008551Phase 2/3
- Effects of Empagliflozin on Cardiac Structure in Patients With Type 2 DiabetesStatus unknownNCT02998970Phase 4
- Pilot Study to Explore the Efficacy of DAPAglifozin as add-on to Closed-loop Control in Patients With Type 1 DiabetesCompletedNCT02987738Phase 1
- Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular EdemaTerminatedNCT02985242Phase 4
- Dapagliflozin + Saxagliptin in a Basal-bolus Insulin TreatmentTerminatedNCT02965443Phase 4
- The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 DiabetesStatus unknownNCT02964715Phase 4
- Effect of Sodium Glucose Co-transporter 2 Inhibitor on Inflammatory Cytokine in Type 2 DiabetesCompletedNCT02964572Not applicable
- Does Dapagliflozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?CompletedNCT02956811Phase 4
- A Drug to Drug Interaction Study of Sotagliflozin With Midazolam and MetoprololCompletedNCT02940379Phase 1
- Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 DiabeticsCompletedNCT02932436Phase 4
- Effect of Anti-diabetic Drugs on Glycemic VariabilityCompletedNCT02925559Phase 4
- Assessment of Dapagliflozin Effect on Diabetic Endothelial Dysfunction of Brachial ArteryCompletedNCT02919345Phase 4
- Study to Asses the Effect of Dapagliflozin on Central Blood Pressure Reduction.Status unknownNCT02919059Phase 4
- A Study of ASP1941 in Combination With Insulin in Patients With Type 1 Diabetes MellitusCompletedNCT02897219Phase 3
- Genetics of Response to CanagliflozinActive, not recruitingNCT02891954Phase 1
- The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 DiabetesCompletedNCT02890745Phase 2
- Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.TerminatedNCT02887677Phase 4
- HbA1c Variability in Type II DiabetesActive, not recruitingNCT02879409Not applicable
- Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and PioglitazoneCompletedNCT02875821Phase 4
- Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND StudyCompletedNCT02874807Phase 2/3
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02865668Phase 1
- Evaluate the Drug-drugs Interaction Between Lobeglitazone and EmpagliflozinStatus unknownNCT02854748Phase 1
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02851212Phase 1
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02851095Phase 1
- Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin TherapyCompletedNCT02847091Phase 4
- A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted ParticipantsCompletedNCT02846506Phase 1
- Evaluation of the Tubular Effects of Dapagliflozin Using 1HNMR SpectroscopyCompletedNCT02798757Phase 4
- SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation.CompletedNCT02798744Phase 4
- The Role of Glucagon in the Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-glucose Co-transporter-2 InhibitorsCompletedNCT02792400Not applicable
- Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female VolunteersCompletedNCT02782624Phase 1
- A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 DiabetesCompletedNCT02765204Phase 4
- Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 DiabetesCompletedNCT02752113Phase 3
- Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic PatientsCompletedNCT02751398Phase 4
- Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE StudyCompletedNCT02729766Phase 2/3
- SGLT2 Inhibition and Left Ventricular MassTerminatedNCT02728453Phase 4
- Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2Status unknownNCT02719756Phase 4
- Effect of DapagliFLOzin on Quality of Life in Patients With Type 2 Diabetes in a Real Clinical PrActiceWithdrawnNCT02719132Phase 4
- SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitisCompletedNCT02696941Phase 1
- The PRE-D Trial: Effect of Dapagliflozin, Metformin and Physical Activity in Pre-diabetesCompletedNCT02695810Phase 2
- Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During RamadanCompletedNCT02694263Phase 4
- Effect of Empagliflozin on Liver Fat Content in Patients With Type 2 DiabetesCompletedNCT02686476Not applicable
- TriMaster: Study of a DPP4 Inhibitor, SGLT2 Inhibitor and Thiazolidinedione as Third Line Therapy in Patients With Type 2 Diabetes.CompletedNCT02653209Phase 4
- SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLDCompletedNCT02649465Phase 4
- Study to Evaluate Sotagliflozin in Subjects With Varying Degrees of Renal FunctionCompletedNCT02647918Phase 1
- Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 DiabetesCompletedNCT02637973Phase 4